Workflow
Zevra Therapeutics(ZVRA) - 2025 Q1 - Quarterly Results
ZVRAZevra Therapeutics(ZVRA)2025-04-07 12:04

Financial Transactions - Zevra Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of 150.0milliononApril1,2025[4][5].−ThecompanyreceivedthePriorityReviewVoucherwhenMIPLYFFA(arimoclomol)wasapprovedbytheFDAfortreatingneurologicalmanifestationsofNiemann−PickdiseasetypeC[4].−TheAssetSalewasexecutedunderaPRVTransferAgreementdatedFebruary26,2025[5].−ThepressreleaserelatedtotheAssetSalewasissuedonApril7,2025[6][11].FinancialPosition−AsofMarch31,2025,thecompany′scash,cashequivalents,andinvestmentstotaledapproximately150.0 million on April 1, 2025[4][5]. - The company received the Priority Review Voucher when MIPLYFFA (arimoclomol) was approved by the FDA for treating neurological manifestations of Niemann-Pick disease type C[4]. - The Asset Sale was executed under a PRV Transfer Agreement dated February 26, 2025[5]. - The press release related to the Asset Sale was issued on April 7, 2025[6][11]. Financial Position - As of March 31, 2025, the company's cash, cash equivalents, and investments totaled approximately 68.7 million[6][8]. - The cash and investment figures are based on preliminary unaudited information and management estimates for the quarter ended March 31, 2025[9]. - The company has not yet completed its financial closing procedures for the quarter ended March 31, 2025, and the figures are subject to change[9]. - The independent registered public accounting firm has not reviewed the preliminary estimates provided[9]. Forward-Looking Statements - Forward-looking statements regarding the company's financial position are subject to various risks and uncertainties[10]. - The company may update forward-looking statements in the future but disclaims any obligation to do so unless required by law[10].